Completed
Molecularly Imprinted Polymer Sensors of Modified Nucleosides for Non-invasive Monitoring, of Cancer Therapy: Impact of Surgical Resection of Metastasis on Urinary Excretion of Modified Nucleosides.
What is being collected
Data Collection
Collected from today forward - ProspectiveNo DNA Sample
Who is being recruted
Colonic Diseases+12
+ Digestive System Diseases
+ Digestive System Neoplasms
Over 18 Years
+14 Eligibility Criteria
How is the trial designed
Case-Control
Comparing exposures between individuals with and without disease in order to identify potential risk factors.Observational
Study Start: September 2012
Summary
Principal SponsorInstitut National de la Santé Et de la Recherche Médicale, France
Last updated: December 7, 2016
Sourced from a government-validated database.Claim as a partner
Study start date: September 1, 2012
Actual date on which the first participant was enrolled.Observational, non randomized study aimed at measuring the effect of surgical resection of metastasis in the urinary concentrations of physiological modified nucleosides in 45 patients with metastatic colorectal cancer.
Principal SponsorInstitut National de la Santé Et de la Recherche Médicale, France
Last updated: December 7, 2016
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
10 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Case-Control
These studies compare people who have a disease (cases) with those who don't (controls). The goal is to look back at previous exposures or risk factors to identify what might have contributed to the disease.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Colonic DiseasesDigestive System DiseasesDigestive System NeoplasmsGastrointestinal DiseasesGastrointestinal NeoplasmsIntestinal DiseasesIntestinal NeoplasmsNeoplasms by SiteNeoplastic ProcessesPathologic ProcessesRectal DiseasesPathological Conditions, Signs and SymptomsNeoplasm MetastasisNeoplasmsColorectal Neoplasms
Criteria
7 inclusion criteria required to participate
0 to 3 prior chemotherapy lines; Signed informed consent
At least one measurable metastatic lesion (RECIST criteria)
Estimated life expectancy exceeding 3 months
Good haematological, hepatic and renal functions
Show More Criteria
7 exclusion criteria prevent from participating
Clinical or laboratory finding suggesting possible abnormalities in nucleosides urinary excretion
Person with legal restriction to participate into clinical research, according to the current law in France
Poor haematological, hepatic or renal functions
Pregnancy or breast-feeding during the previous month
Show More Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Treatment Groups
Study Objectives
2 intervention groups are designated in this study
This study does not include a placebo group
Treatment Groups
Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
CompletedOne Study Center